Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review
Y Du, Y Wang, T Zhang, J Li, H Song… - Expert Review of …, 2023 - Taylor & Francis
Introduction Studies on economic evaluations of the 13-valent pneumococcal conjugate
vaccine (PCV13) have been increasing over the last decade. No systematic reviews have …
vaccine (PCV13) have been increasing over the last decade. No systematic reviews have …
[HTML][HTML] Pneumococcal vaccination in children: a systematic review and meta-analysis of cost-effectiveness studies
Abstract Objectives Pneumococcal conjugate vaccines (PCVs) have significantly reduced
disease burden caused by Streptococcus pneumoniae, a leading cause of childhood …
disease burden caused by Streptococcus pneumoniae, a leading cause of childhood …
Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis
Background Introduction of pneumococcal conjugate vaccines (PCVs) has substantially
reduced disease burden due to Streptococcus pneumoniae, a leading cause of childhood …
reduced disease burden due to Streptococcus pneumoniae, a leading cause of childhood …
COVID-19 vaccine uptake and associated factors among adolescents and youths: Findings and implications for future vaccination programmes
Adolescents and youths are a key part of the population that needs to be protected against
the coronavirus disease 2019 (COVID-19). This is because they are more likely to spread …
the coronavirus disease 2019 (COVID-19). This is because they are more likely to spread …
[HTML][HTML] Pneumococcal disease: a systematic review of health utilities, resource use, costs, and economic evaluations of interventions
Background Pneumococcal diseases cause substantial mortality, morbidity, and economic
burden. Evidence on data inputs for economic evaluations of interventions targeting …
burden. Evidence on data inputs for economic evaluations of interventions targeting …
Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomized controlled trial of 10-valent and 13-valent pneumococcal …
WS Pomat, AHJ Van Den Biggelaar… - Clinical Infectious …, 2019 - academic.oup.com
Background There are little data on the immunogenicity of PCV10 and PCV13 in the same
high-risk population. Methods PCV10 and PCV13 were studied head-to-head in a …
high-risk population. Methods PCV10 and PCV13 were studied head-to-head in a …
A systematic review of economic evaluations of active tuberculosis treatments
Background: The disease burden of active tuberculosis (TB) is considerable, but systematic
reviews of economic evaluations of active TB treatments are scarce. Methods: PubMed …
reviews of economic evaluations of active TB treatments are scarce. Methods: PubMed …
[HTML][HTML] Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia—results of a phase …
E Clarke, AO Bashorun, M Okoye, A Umesi, MB Hydara… - Vaccine, 2020 - Elsevier
Background A more affordable pneumococcal conjugate vaccine (PCV) that provides
comparable protection to current PCVs is needed to ensure sustainable access in resource …
comparable protection to current PCVs is needed to ensure sustainable access in resource …
An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand
Background A previous cost-effectiveness analysis (CEA) showed that Pneumococcal
Conjugate Vaccine (PCV) 10 and PCV13 were not cost-effective for universal immunization …
Conjugate Vaccine (PCV) 10 and PCV13 were not cost-effective for universal immunization …
Comprehensive vaccine design for commensal disease progression
CH Jones, G Zhang, R Nayerhoda, M Beitelshees… - Science …, 2017 - science.org
Commensal organisms with the potential to cause disease pose a challenge in developing
treatment options. Using the example featured in this study, pneumococcal disease begins …
treatment options. Using the example featured in this study, pneumococcal disease begins …